Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Must have received: radical prostatectomy

Participants must have undergone radical prostatectomy

Must have received: local therapy (surgery and any adjuvant/salvage radiation therapy)

Participants must have completed local therapy by surgery, and any adjuvant/salvage radiation therapy (if required), at least 3 months prior to entry

Cannot have received: LHRH agonist or nonsteroidal antiandrogen

Exception: Neoadjuvant/adjuvant androgen deprivation therapy with radiation or at prostatectomy is acceptable if no PSA progression and ≤24 months duration

Prior treatment with an LHRH agonist or nonsteroidal antiandrogen, except in the following circumstances: Neoadjuvant/adjuvant androgen deprivation therapy administered with radiation therapy or at the time of prostatectomy is acceptable, provided that there was no evidence of PSA progression while on treatment. In this situation, patients must not have received more than 24 months of androgen deprivation treatment. Other treatment with androgen deprivation therapy is prohibited.

Cannot have received: immunosuppressive therapy (chemotherapy or chronic corticosteroids >10 mg prednisone/day)

Participants cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy or chronic treatment dose corticosteroids (greater than the equivalent of 10 mg prednisone per day), within 3 months of the first vaccination.

Cannot have received: other potential or experimental therapies for prostate cancer

Participants previously treated with other potential or experimental therapies for prostate cancer must have discontinued these treatments and completed at least a 4 week washout prior to beginning treatment.